Press release
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna
About this update from Moderna, Inc.
[{"type":"text","content":"All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has authorized its updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for individuals aged six months and older. Moderna is on track to deliver the updated vaccine in time for the 2025-2026 vaccination season.All Spikevax pre-filled syringe (PFS) doses for the Canadian market will now be manufactured domestically, marking the first time Canada's entire PFS format is produced at home. The drug substance will be produced at Moderna's new facility in Laval, Quebec, with fill-finish operations completed by Novocol Pharma in Cambridge, Ontario. These Canadian-made doses are expected to be available for this fall.\"This approval is a regulatory milestone and a testament to Canada's growing leadership in biomanufacturing and public health resilience,\" said Stéphane Bancel, Chief Executive Officer of Moderna. \"Thanks to Health Canada's timely and thorough review, we are proud to supply Spikevax doses to communities across the country, including, for the first time this year, doses produced in Canada.\"Moderna's updated COVID-19 vaccine targeting LP.8.1 has already been granted approval by regulators in Europe, Japan, Switzerland and other countries. Additional regulatory applications are under review around the world in preparation for the coming season.Access and DistributionEligibility for the public vaccination program is set by each province and territory. Those who meet provincial criteria will receive the vaccine free of charge. For individuals not covered under the public programs, efforts are ongoing with private insurers and payers to streamline access and reimbursement within the private sector.Canadians are encouraged to consult their provincial or territorial health authorities for the latest information on eligibility and availability.Regulatory BasisHealth Canada's authorization is based on a comprehensive body of evidence submitted by Moderna, including clinical, non-clinical, and real-world data supporting the vaccine's safety and efficacy.[1][1] Moderna Canada. SPIKEVAX® Product Monograph. August 21, 2025.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the adv...